Stock listing
NASDAQ:AMLX Amylyx Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Amylyx Pharmaceuticals, Inc.
Follow Amylyx Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AMLX
$26.02 USD -0.60 (-2.3%)
Close on Nov 20, 2026
- Day range
- $25.52 – $26.40 USDNov 20, 2026
- Volume
- 1.14M sharesNov 20, 2026
- Market cap
- $3.35B USDAt the close on Nov 20, 2026 · price × 128.6M shares outstanding
- 52-week range
- $10.83 – $41.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $53.54M USDMedian day 1.38M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AMLX · Home | $26.02 USD | -0.60 (-2.3%) | 1,135,833 | $25.64 | $26.40 | $25.52 | $26.62 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AMLX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $26.02 | -0.60 | -2.3% | $25.64 | $26.40 | $25.52 | 1,135,833 | |
| $26.62 | -0.90 | -3.3% | $27.49 | $28.17 | $26.24 | 1,510,531 | |
| $27.52 | -0.28 | -1.0% | $27.50 | $27.66 | $26.61 | 1,175,963 | |
| $27.80 | -2.49 | -8.2% | $30.19 | $31.35 | $27.55 | 1,578,180 | |
| $30.29 | +0.43 | +1.4% | $29.66 | $30.72 | $28.86 | 1,618,681 | |
| $29.86 | -1.94 | -6.1% | $31.43 | $31.57 | $29.79 | 1,473,324 | |
| $31.80 | +0.89 | +2.9% | $31.16 | $31.88 | $30.46 | 2,001,226 | |
| $30.91 | +0.70 | +2.3% | $29.94 | $31.22 | $29.76 | 1,424,755 | |
| $30.21 | +0.71 | +2.4% | $29.85 | $30.32 | $28.76 | 1,297,563 | |
| $29.50 | +1.88 | +6.8% | $27.73 | $29.58 | $27.50 | 1,860,648 | |
| $27.62 | -1.78 | -6.1% | $30.23 | $30.23 | $27.48 | 2,210,140 | |
| $29.40 | +0.20 | +0.7% | $30.65 | $30.68 | $27.90 | 1,586,254 | |
| $29.20 | +1.16 | +4.1% | $28.52 | $29.46 | $28.21 | 1,202,704 | |
| $28.04 | -0.82 | -2.8% | $28.84 | $29.51 | $27.61 | 1,161,832 | |
| $28.86 | +0.18 | +0.6% | $28.41 | $29.09 | $28.00 | 989,514 | |
| $28.68 | +0.61 | +2.2% | $28.13 | $29.13 | $28.10 | 905,442 | |
| $28.07 | -0.23 | -0.8% | $28.11 | $28.48 | $27.58 | 1,064,464 | |
| $28.30 | +1.21 | +4.5% | $27.28 | $28.32 | $26.86 | 1,122,468 | |
| $27.09 | -0.11 | -0.4% | $27.25 | $27.98 | $26.23 | 1,371,103 | |
| $27.20 | -1.37 | -4.8% | $28.46 | $28.46 | $27.06 | 1,158,793 | |
| $28.57 | -0.46 | -1.6% | $28.84 | $30.00 | $28.51 | 1,307,959 | |
| $29.03 | +0.26 | +0.9% | $28.96 | $29.78 | $28.81 | 1,626,560 | |
| $28.77 | +1.44 | +5.3% | $27.54 | $29.23 | $27.15 | 1,613,173 | |
| $27.33 | +0.99 | +3.8% | $26.48 | $27.35 | $26.27 | 1,380,993 | |
| $26.34 | -1.31 | -4.7% | $27.65 | $27.65 | $26.20 | 1,150,596 | |
| $27.65 | +0.62 | +2.3% | $27.68 | $28.34 | $27.45 | 882,656 | |
| $27.03 | +0.18 | +0.7% | $26.80 | $27.77 | $26.46 | 1,166,178 | |
| $26.85 | -0.63 | -2.3% | $27.49 | $27.69 | $26.80 | 1,059,784 | |
| $27.48 | -0.66 | -2.3% | $28.04 | $28.49 | $27.40 | 1,106,108 | |
| $28.14 | +0.94 | +3.5% | $27.32 | $28.60 | $26.94 | 1,471,500 | |
| $27.20 | -0.23 | -0.8% | $27.01 | $27.53 | $26.04 | 2,622,162 | |
| $27.43 | -0.61 | -2.2% | $27.72 | $28.46 | $27.21 | 2,056,710 | |
| $28.04 | +0.26 | +0.9% | $27.97 | $28.50 | $27.00 | 1,279,463 | |
| $27.78 | -0.01 | 0.0% | $27.92 | $28.09 | $27.34 | 941,080 | |
| $27.79 | -0.29 | -1.0% | $28.50 | $28.81 | $27.64 | 912,394 | |
| $28.08 | -1.02 | -3.5% | $28.62 | $29.28 | $27.55 | 1,354,104 | |
| $29.10 | -0.18 | -0.6% | $29.47 | $29.62 | $28.64 | 1,307,046 | |
| $29.28 | -0.57 | -1.9% | $29.87 | $30.10 | $28.99 | 1,177,757 | |
| $29.85 | +0.36 | +1.2% | $29.10 | $30.14 | $28.71 | 1,020,546 | |
| $29.49 | -0.65 | -2.2% | $30.28 | $30.70 | $29.47 | 1,294,475 | |
| $30.14 | -0.465 | -1.5% | $30.73 | $31.00 | $29.83 | 1,420,508 | |
| $30.61 | -2.395 | -7.3% | $32.88 | $33.02 | $30.53 | 1,824,887 | |
| $33.00 | +0.61 | +1.9% | $32.52 | $33.19 | $32.25 | 1,383,682 | |
| $32.39 | -0.02 | -0.1% | $32.55 | $33.16 | $31.90 | 1,005,644 | |
| $32.41 | -1.53 | -4.5% | $34.21 | $34.21 | $32.25 | 2,048,794 | |
| $33.94 | +1.31 | +4.0% | $33.33 | $34.35 | $32.95 | 1,592,060 | |
| $32.63 | -0.52 | -1.6% | $33.05 | $33.75 | $32.10 | 1,366,183 | |
| $33.15 | -0.49 | -1.5% | $33.22 | $33.54 | $32.36 | 1,828,400 | |
| $33.64 | +2.02 | +6.4% | $31.84 | $33.96 | $31.57 | 1,925,353 | |
| $31.62 | -0.47 | -1.5% | $32.09 | $33.00 | $31.37 | 1,712,745 | |
| $32.09 | -0.31 | -1.0% | $31.81 | $32.57 | $31.44 | 1,777,482 | |
| $32.40 | -1.48 | -4.4% | $33.50 | $34.35 | $32.30 | 1,287,490 | |
| $33.88 | -0.22 | -0.6% | $33.49 | $34.72 | $33.10 | 1,166,534 | |
| $34.10 | +0.14 | +0.4% | $33.38 | $34.24 | $33.38 | 885,518 | |
| $33.96 | -0.53 | -1.5% | $34.49 | $35.31 | $33.73 | 1,556,792 | |
| $34.49 | +0.68 | +2.0% | $34.00 | $35.48 | $34.00 | 1,938,485 | |
| $33.81 | +0.06 | +0.2% | $33.49 | $34.21 | $32.99 | 1,821,535 | |
| $33.75 | -0.99 | -2.8% | $34.77 | $35.09 | $32.98 | 2,728,978 | |
| $34.74 | -2.44 | -6.6% | $36.78 | $37.68 | $34.48 | 1,361,802 | |
| $37.18 | +0.10 | +0.3% | $36.75 | $38.23 | $36.53 | 1,989,242 | |
| $37.08 | -0.38 | -1.0% | $37.13 | $37.69 | $35.79 | 2,815,491 | |
| $37.46 | -0.69 | -1.8% | $38.50 | $38.88 | $36.84 | 2,147,376 | |
| $38.15 | -0.51 | -1.3% | $38.64 | $39.38 | $37.45 | 3,714,467 | |
| $38.66 | -1.00 | -2.5% | $39.80 | $41.14 | $38.35 | 4,644,894 | |
| $39.66 | +1.06 | +2.7% | $37.49 | $40.44 | $37.37 | 8,540,882 |
- Ticker
- NASDAQ:AMLX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 14, 2026
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Latest earnings call · Nov 5, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 38 slides
Latest news
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Nov 14, 2026
Closed $27.80 (-8.2%) on Nov 16, 2026
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $27.62 (-6.1%) on Nov 5, 2026
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
Nov 4, 2026
Closed $29.40 (+0.7%) on Nov 4, 2026
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Nov 3, 2026
Closed $29.20 (+4.1%) on Nov 3, 2026
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Nov 2, 2026
Closed $28.04 (-2.8%) on Nov 2, 2026
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Sep 23, 2026
Closed $30.61 (-7.3%) on Sep 23, 2026
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Sep 8, 2026
Closed $33.88 (-0.6%) on Sep 8, 2026
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Aug 19, 2026
Closed $39.66 (+2.7%) on Aug 20, 2026
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Aug 18, 2026
Closed $38.60 (+9.9%) on Aug 19, 2026
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Aug 18, 2026
Closed $35.11 (+63.8%) on Aug 18, 2026
Amylyx Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 141 in all · newest Nov 14, 2026 · oldest 2022
- Calls
- 17 calls with a replay · 17 with a transcript · latest Nov 5, 2026
- Decks
- 11 decks · latest September 2026
Where Amylyx Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AMLX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AMLX | BOATS | United States | USD |
Valuation
Price/book 4.4× against a median of 4.1×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.58B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.21
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLX | US$3.35B | US$2.58B | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.21 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336 | US$3.57B | US$3.43B | 7.6× | 5.1× | n/a | 2.7× | 69.9% | 0.0× | n/a |
| Relay Therapeutics, Inc. · NASDAQ:RLAY | US$3.56B | US$2.74B | n/a | 265× | n/a | 4.3× | n/a | 0.0× | 1.48 |
| Enliven Therapeutics, Inc. · NASDAQ:ELVN | US$3.42B | US$2.54B | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 0.89 |
| Disc Medicine, Inc. · NASDAQ:IRON | US$3.42B | US$2.80B | n/a | n/a | n/a | 5.7× | n/a | 0.1× | 0.94 |
| Viridian Therapeutics, Inc. · NASDAQ:VRDN | US$3.40B | US$2.69B | n/a | 102× | n/a | 5.9× | n/a | 0.4× | 1.00 |
| Parabilis Medicines, Inc. · NASDAQ:PBLS | US$3.39B | US$2.53B | n/a | n/a | n/a | 3.4× | n/a | 0.0× | n/a |
| Caliway Biopharmaceuticals Co Ltd · TWSE:6919 | US$3.38B | US$3.27B | n/a | n/a | n/a | 12.7× | n/a | 0.0× | n/a |
| Iovance Biotherapeutics, Inc. · NASDAQ:IOVA | US$3.19B | US$2.86B | n/a | 7.5× | n/a | 3.9× | −58.2% | 0.1× | 1.62 |
| AbCellera Biologics Inc. · NASDAQ:ABCL | US$3.16B | US$2.53B | n/a | 37.3× | n/a | 3.0× | −218.5% | 0.1× | 2.42 |
| Viking Therapeutics, Inc. · NASDAQ:VKTX | US$3.16B | US$2.20B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.31 |
| Median of the others | US$3.40B | US$2.72B | 7.6× | 37.3× | 4.1× | −58.2% | 0.0× | 1.31 |
Forecasts
11 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 43.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.51 · 8 analysts
- Revenue, year to Dec 2026
- 55.56K · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Josh Cohen | Co-CEO of Amylyx |
| Justin Klee | Co-CEO of Amylyx |
| James M. Frates | Chief Financial Officer |
| Gina M. Mazzariello | Chief Legal Officer & General Counsel |
| Camille L. Bedrosian | Chief Medical Officer |
| Dan Monahan | Chief Commercial Officer |
| Linda A. Arsenault | Chief Human Resources Officer |
| Tom Holmes | Chief Technical Operations Officer |
Board
| Director | Role |
|---|---|
| George Milne | Chairman |
| Bernhardt G. Zeiher | Director |
| Daphne Quimi | Director |
| Kari Firestone | Director |
| Paul Fonteyne | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2025 Earnings Call | Tue, Mar 03, 2026 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2024 Earnings Call | Tue, Mar 04, 2025 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
All 17 calls
| Call | When | Status |
|---|---|---|
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2023 Earnings Call | Thu, Feb 22, 2024 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 8:00 AM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2023 Earnings Call | Thu, Aug 10, 2023 · 4:30 PM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2023 Earnings Call | Thu, May 11, 2023 · 4:00 PM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2022 Earnings Call | Mon, Mar 13, 2023 · 4:30 PM ET | Replay |
| Amylyx Pharmaceuticals (NASDAQ:AMLX) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −6.0% |
| Q2 2026 | Aug 6, 2026 · Before open | +10.7% |
| Q1 2026 | May 7, 2026 · Before open | −5.3% |
| Q4 2025 | Mar 3, 2026 · Before open | −7.8% |
| Q3 2025 | Nov 6, 2025 · Before open | −5.9% |
| Q2 2025 | Aug 7, 2025 · Before open | −4.3% |
| Q1 2025 | May 8, 2025 · Before open | −6.0% |
| Q4 2024 | Mar 4, 2025 | +12.0% |
| Q3 2024 | Nov 7, 2024 · Before open | +5.1% |
| Q2 2024 | Aug 8, 2024 · Before open | −4.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −2.1% |
| Q4 2023 | Feb 22, 2024 · Before open | +21.1% |
| Q3 2023 | Nov 9, 2023 · Before open | −31.9% |
| Q2 2023 | Aug 10, 2023 · After close | +2.0% |
| Q1 2023 | May 11, 2023 · After close | −4.0% |
| Q4 2022 | Mar 13, 2023 · After close | +9.4% |
| Q3 2022 | Nov 10, 2022 · After close | −3.9% |
| Q2 2022 | Aug 11, 2022 · After close | −3.6% |
| Q1 2022 | May 12, 2022 · After close | +13.0% |
| Q4 2021 | Mar 30, 2022 · After close | −13.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 38 slides | September 2026 |
| Phase 3 LUCIDITY Trial of Avexitide in PBH Topline Data Conference Call (August 2026) | Conference | 17 slides | Aug 18, 2026 |
| Investor Presentation (March 2026) | Investor deck | 41 slides | Mar 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 40 slides | Mar 3, 2026 |
| Investor Presentation (January 2026) | Investor deck | 40 slides | Jan 8, 2026 |
| Technical Presentation (2025) | Technical | 14 slides | 2025 |
| Technical Presentation (July 2024) | Technical | 27 slides | Jul 10, 2024 |
| Technical Presentation (2024) | Technical | 20 slides | 2024 |
| Corporate Update (July 2023) | Corporate update | 24 slides | Jul 26, 2023 |
| ENDO 2022 | Conference | 15 slides | Jun 11, 2022 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ENDO (Endocrine Society) | Conference | 6 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: US$500.2M · US$35.5 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead) Use of proceeds: Pre-commercial activities for avexitide including manufacturing capacity, research and development, working capital and general corporate purposes | Aug 20, 2026 |
| Public offering of common stock Announced: US$175M · US$10 a share · Leerink Partners +2 Dealers: Leerink Partners (lead), Guggenheim Securities (lead), H.C. Wainwright & Co. (lead) Use of proceeds: Avexitide commercial readiness, research and development, working capital and general corporate purposes | Sep 10, 2025 |
| Public offering of common stock Announced: about US$60M · US$3.5 a share · Leerink Partners Dealers: Leerink Partners (lead) Use of proceeds: Advance preparations for commercialization and pipeline programs, working capital and general corporate purposes | Jan 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Jan 6, 2022.
- Price
- US$19.00 a share
- Shares offered
- 10,000,000 shares of common stock
- Offering size
- US$190 million
- Underwriters' option
- Up to 1,500,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, SVB Leerink, Evercore ISI, H.C. Wainwright & Co. · In the order on the cover
- Shares delivered
- On or about Jan 11, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 26, 2021 |
| Filed publicly | Dec 16, 2021 |
| Amended once | Jan 3, 2022 |
| Shares registered with an exchange | Jan 4, 2022 |
| Declared effective by the SEC | Jan 6, 2022 |
| Final prospectus, with the price | Jan 10, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 10, 2022 |
| EFFECT · Notice that a registration is effective | Jan 6, 2022 |
| S-1MEF · Registration of more shares for the same offering | Jan 6, 2022 |
| CERT · Exchange's certificate of listing | Jan 6, 2022 |
| CORRESP · Letter to the SEC | Jan 4, 2022 |
| CORRESP · Letter to the SEC | Jan 4, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 4, 2022 |
| FWP · Free writing prospectus | Jan 4, 2022 |
| S-1/A · Registration statement, amended | Jan 3, 2022 |
| CORRESP · Letter to the SEC | Dec 16, 2021 |
All 19 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Dec 16, 2021 |
| UPLOAD · Letter from the SEC | Dec 9, 2021 |
| DRS/A · Draft registration statement, amended | Nov 26, 2021 |
| DRSLTR · Letter to the SEC with a draft | Nov 24, 2021 |
| UPLOAD · Letter from the SEC | Nov 23, 2021 |
| DRSLTR · Letter to the SEC with a draft | Oct 20, 2021 |
| DRS/A · Draft registration statement, amended | Oct 20, 2021 |
| UPLOAD · Letter from the SEC | May 28, 2021 |
| DRS · Draft registration statement | Apr 26, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 10, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 87.4M | 380.8M | 22.2M | 285.0K | 650.0K | 1.43M |
| Cost of revenue | 0 | 5.95M | 25.4M | 2.99M | 52.0K | 24.6M | 11.9M |
| Gross profit | -525.0K | 45.2M | 355.3M | 19.2M | 285.0K | -23.9M | -10.5M |
| Research and development | 90.4M | 104.1M | 128.2M | 93.5M | 44.0M | 24.6M | 11.9M |
| Selling, general and administrative | 62.9M | 114.3M | 188.4M | 127.1M | 38.9M | 14.9M | 3.08M |
| Operating income | -153.3M | -314.7M | 38.8M | -201.3M | -82.7M | -39.0M | -13.6M |
| Depreciation and amortization | 525.0K | 904.0K | 1.09M | 487.0K | 52.0K | 1.00K | 13.6M |
| EBITDA | -152.8M | -313.8M | 39.9M | -200.9M | -82.6M | -39.0M | 0 |
| Interest expense | 4.29M | 36.0K | 2.29M | 1.28M | |||
| Income before tax | -144.7M | -302.1M | 54.3M | -197.6M | -87.9M | -42.3M | -13.7M |
| Income tax | 46.0K | -393.0K | 5.03M | 774.0K | -52.0K | 2.56M | 1.10M |
| Net income | -144.7M | -301.7M | 49.3M | -198.4M | -87.9M | -42.3M | -14.8M |
| Earnings per share, basic | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 | -0.75 | -0.26 |
| Earnings per share, diluted | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 226.7M | 77.4M | 170.2M | 62.5M | 50.2M | 12.9M | 3.06M |
| Short-term investments | 90.3M | 99.1M | 201.2M | 284.4M | 45.9M | 0 | |
| Receivables | 88.0K | 447.0K | 40.0M | 15.3M | 0 | ||
| Inventory | 0 | 38.3M | 9.77M | 0 | |||
| Current assets | 323.7M | 189.4M | 464.7M | 382.1M | 105.0M | 13.6M | 3.20M |
| Property, plant and equipment | 310.0K | 961.0K | 2.69M | 2.61M | 474.0K | 151.0K | |
| Total assets | 332.6M | 193.6M | 517.5M | 391.5M | 105.6M | 14.1M | 3.22M |
| Accounts payable | 3.52M | 2.94M | 22.1M | 6.26M | 4.37M | 3.61M | 2.19M |
| Current liabilities | 22.7M | 28.4M | 82.0M | 46.6M | 17.4M | 7.33M | 4.53M |
| Long-term debt | 1.43M | 14.9M | |||||
| Total debt | 5.96M | 1.98M | 4.24M | 6.28M | 1.43M | 14.9M | |
| Total liabilities | 27.4M | 28.9M | 84.0M | 50.8M | 17.4M | 80.8M | 28.6M |
| Shareholders' equity | 305.3M | 164.8M | 433.4M | 340.6M | -151.2M | -66.7M | -25.4M |
| Shares outstanding | 109.9M | 68.6M | 67.7M | 66.5M | 7.02M | 56.5M | 56.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -123.3M | -167.6M | 11.9M | -179.9M | -74.8M | -36.7M | -10.7M |
| Capital spending | -138.0K | -157.0K | -1.24M | -2.53M | -353.0K | -151.0K | -151.0K |
| Free cash flow | -123.5M | -167.8M | 10.7M | -182.4M | -75.2M | -36.8M | -10.7M |
| Cash from investing | 14.0M | 75.7M | 92.1M | -239.0M | -46.4M | -151.0K | -151.0K |
| Cash from financing | 257.0M | 348.0K | 3.54M | 431.8M | 158.5M | 46.8M | 668.0K |
| Share buybacks | -3.31M | 434.6M | |||||
| Change in cash | 148.8M | -92.1M | 107.7M | 12.9M | 37.3M | 9.97M | 3.09M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 20, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Aug 18, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Mar 3, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 9, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 4, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2025 | Annual report | SEC |
| POSASR | Mar 4, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 4, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jan 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 25, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 26, 2024 | Big-stake notice | SEC |
This page holds 200 of 448 filings. Open Filings
Cap table
Built by 6ix from Amylyx Pharmaceuticals, Inc.’s releases · as of Oct 26, 2026
- Common shares
- 128,562,904
- Fully diluted
- 128,562,904
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 128,562,904 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 128,562,904 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Paul Fonteyne Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Apellis Pharmaceuticals, Inc. (Director · Since at least Apr 2, 2020); Covetrus Inc (Director · Jul 1, 2021 – Oct 13, 2022 · Past); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past) | Director · Since at least Jan 6, 2022 |
| Camille L. Bedrosian Other companies: Rhythm Pharmaceuticals, Inc. (Director · Since at least Dec 9, 2020); Crinetics Pharmaceuticals, Inc. (Director · Since at least Sep 1, 2020); Ultragenyx Pharmaceutical Inc. (EVP and Chief Medical Officer · Jan 29, 2018 – Mar 1, 2023 · Past); Ariad Pharmaceuticals Inc (VP, Chief Medical Officer · Apr 16, 2007 – Apr 16, 2007 · Past) | Chief Medical Officer · Since at least Nov 27, 2023 |
| Bernhardt G. Zeiher Other companies: Abeona Therapeutics Inc. (Director · Since at least Aug 8, 2024); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Apr 4, 2023) | Director · Since at least Mar 14, 2024 |
| Daphne Quimi Other companies: Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Amicus Therapeutics Inc (Chief Financial Officer · Oct 1, 2020 – Jan 17, 2023 · Past) | Director · Since at least Jan 6, 2022 |
| George M Milne Jr Other companies: Charles River Laboratories International, Inc. (Director · Mar 1, 2021 – May 7, 2021 · Past); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2023 · Past) | Director · Since at least Jan 6, 2022 |
| James M. Frates Other companies: Sage Therapeutics Inc (Director · Since at least Jul 17, 2014); Alkermes plc (SVP, Alks Inc; CFO ALKS · May 2, 2006 – May 14, 2020 · Past) | Chief Financial Officer · Since at least Jan 6, 2022 |
| Dan Monahan | Chief Commercial Officer · Since at least Mar 4, 2025 |
| George Milne | Chairman · Since at least Oct 7, 2026 |
| Gina M. Mazzariello | Chief Legal Officer & General Counsel · Since at least Feb 22, 2022 |
| Josh Cohen | Co-CEO of Amylyx · Since at least Sep 14, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Joshua B Cohen | Co-Chief Executive Officer, Director · Since at least Jan 6, 2022 |
| Justin Klee | Co-CEO of Amylyx · Since at least Jan 6, 2022 |
| Karen Firestone | Director · Since at least Mar 16, 2023 |
| Kari Firestone | Director · Since at least Nov 5, 2026 |
| Linda A. Arsenault | Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Margaret Olinger | Chief Commercial Officer · Jan 6, 2022 – Dec 27, 2023 · Past |
| Patrick D Yeramian | Chief Medical Officer · Jan 6, 2023 – Jan 9, 2024 · Past |
| Tom Holmes | Chief Technical Operations Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Amylyx Pharmaceuticals, Inc.